Roland Meisel

Prof. Roland Meisel


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in European Journal of Cancer
Verified
Journal Article
Closed access
BWBarbara C Worst
Barbara C Worst
CTCornelis M Van Tilburg
Cornelis M Van Tilburg
GBGnana Prakash Balasubramanian
Gnana Prakash Balasubramanian
PFPetra Fiesel
Petra Fiesel
RWRuth Witt
Ruth Witt
OWOlaf Witt
Olaf Witt

9 August 2021 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
CTCornelis M. van Tilburg
Cornelis M. van Tilburg
EPElke Pfaff
Elke Pfaff
KPKristian W. Pajtler
Kristian W. Pajtler
KLKarin Langenberg
Karin Langenberg
PFPetra Fiesel
Petra Fiesel
OWOlaf Witt
Olaf Witt
INFORM is a prospective, multinational registry gathering clinical and molecular data of relapsed, progressive, or high-risk pediatric patients with cancer. This report describes long-term follow-up of 519 patients in whom molecular alterations were evaluated according to a predefined seven-scale target prioritization algorithm. Mean turnaround time from sample receipt to report was 25.4 days. The highest target priority level was observed in 42 patients (8.1%). Of these, 20 patients received matched targeted treatment with a median progression-free survival of 204 days [95% confidence interval (CI), 99–not applicable], compared with 117 days (95% CI, 106–143; P = 0.011) in all other patients. The respective molecular targets were shown to be predictive for matched treatment response and not prognostic surrogates for improved outcome. Hereditary cancer predisposition syndromes were identified in 7.5% of patients, half of which were newly identified through the study. Integrated molecular analyses resulted in a change or refinement of diagnoses in 8.2% of cases. Significance: The pediatric precision oncology INFORM registry prospectively tested a target prioritization algorithm in a real-world, multinational setting and identified subgroups of patients benefiting from matched targeted treatment with improved progression-free survival, refinement of diagnosis, and identification of hereditary cancer predisposition syndromes. See related commentary by Eggermont et al., p. 2677 . This article is highlighted in the In This Issue feature, p. 2659

18 January 2011 in Leukemia
Verified
Journal Article
Closed access
RMRoland Meisel
Roland Meisel
SBS Brockers
S Brockers
KHK Heseler
K Heseler
ÖDÖ Degistirici
Ö Degistirici
HBH Bülle
H Bülle
WDW Däubener
W Däubener

18 March 2019 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
LSLucas-Sebastian Spitzhorn
Lucas-Sebastian Spitzhorn
MMMatthias Megges
Matthias Megges
WWWasco Wruck
Wasco Wruck
Md Shaifur RahmanMd Shaifur Rahman
Md Shaifur Rahman
JOJörg Otte
Jörg Otte
James AdjayeJames Adjaye
James Adjaye
Primary mesenchymal stem cells (MSCs) are fraught with aging-related shortfalls. Human-induced pluripotent stem cell (iPSC)-derived MSCs (iMSCs) have been shown to be a useful clinically relevant source of MSCs that circumvent these aging-associated drawbacks. To date, the extent of the retention of aging-hallmarks in iMSCs differentiated from iPSCs derived from elderly donors remains unclear. Fetal femur-derived MSCs (fMSCs) and adult bone marrow MSCs (aMSCs) were isolated, corresponding iPSCs were generated, and iMSCs were differentiated from fMSC-iPSCs, from aMSC-iPSCs, and from human embryonic stem cells (ESCs) H1. In addition, typical MSC characterization such as cell surface marker expression, differentiation capacity, secretome profile, and trancriptome analysis were conducted for the three distinct iMSC preparations—fMSC-iMSCs, aMSC-iMSCs, and ESC-iMSCs. To verify these results, previously published data sets were used, and also, additional aMSCs and iMSCs were analyzed. fMSCs and aMSCs both express the typical MSC cell surface markers and can be differentiated into osteogenic, adipogenic, and chondrogenic lineages in vitro. However, the transcriptome analysis revealed overlapping and distinct gene expression patterns and showed that fMSCs express more genes in common with ESCs than with aMSCs. fMSC-iMSCs, aMSC-iMSCs, and ESC-iMSCs met the criteria set out for MSCs. Dendrogram analyses confirmed that the transcriptomes of all iMSCs clustered together with the parental MSCs and separated from the MSC-iPSCs and ESCs. iMSCs irrespective of donor age and cell type acquired a rejuvenation-associated gene signature, specifically, the expression of INHBE, DNMT3B, POU5F1P1, CDKN1C, and GCNT2 which are also expressed in pluripotent stem cells (iPSCs and ESC) but not in the parental aMSCs. iMSCs expressed more genes in common with fMSCs than with aMSCs. Independent real-time PCR comparing aMSCs, fMSCs, and iMSCs confirmed the differential expression of the rejuvenation (COX7A, EZA2, and TMEM119) and aging (CXADR and IGSF3) signatures. Importantly, in terms of regenerative medicine, iMSCs acquired a secretome (e.g., angiogenin, DKK-1, IL-8, PDGF-AA, osteopontin, SERPINE1, and VEGF) similar to that of fMSCs and aMSCs, thus highlighting their ability to act via paracrine signaling. iMSCs irrespective of donor age and cell source acquire a rejuvenation gene signature. The iMSC concept could allow circumventing the drawbacks associated with the use of adult MSCs und thus provide a promising tool for use in various clinical settings in the future.

7 November 2006 in Blood
Verified
Journal Article
Open access
PDF file
RMRoland Meisel
Roland Meisel
LKLisa Kuypers
Lisa Kuypers
UDUta Dirksen
Uta Dirksen
RSRalf Schubert
Ralf Schubert
BGBernd Gruhn
Bernd Gruhn
FGfor the Impfung von Kindern nach allogener Stammzelltransplantation (IKAST) Study Group
for the Impfung von Kindern nach allogener Stammzelltransplantation (IKAST) Study Group
Following allogeneic hematopoietic stem cell transplantation (alloHSCT), children are at risk of life-threatening pneumococcal infections. Whereas vaccination with polysaccharide vaccines fails to elicit protective immunity in most alloHSC transplant recipients, pneumococcal conjugate vaccines may effectively prevent invasive disease by eliciting T-cell–dependent antibody responses. Here, we report safety and immunogenicity in 53 children immunized with a regimen of 3 consecutive doses of a heptavalent pneumococcal conjugate vaccine (7vPCV) in monthly intervals starting 6 to 9 months after alloHSCT. Immunization was well tolerated with no vaccine-related serious adverse events. Serologic response rates evaluable in 43 patients ranged from 41.9% to 86.0% and 58.1% to 93.0% after 2 and 3 vaccinations, respectively, with 55.8% and 74.4% of patients achieving protective antibody levels to all 7 vaccine serotypes. Our study provides the first evidence that vaccination with 7vPCV is safe and elicits protective antipneumococcal antibody responses in pediatric recipients of related or unrelated donor alloHSC transplants within the first year following transplantation. This trial was registered at www.clinicaltrials.gov as NCT00169728.

1 April 2011 in Vaccine
Verified
Journal Article
Closed access
IHInken Hilgendorf
Inken Hilgendorf
MFMathias Freund
Mathias Freund
WJWolfgang Jilg
Wolfgang Jilg
HEHermann Einsele
Hermann Einsele
JGJuan Gea-Banacloche
Juan Gea-Banacloche
RMRoland Meisel
Roland Meisel